Checkmate_Twitter-profile_full-logo.png
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 17:01 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
April 19, 2022 07:00 ET | Checkmate Pharmaceuticals Inc.
Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 13:01 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update
March 29, 2022 16:30 ET | Checkmate Pharmaceuticals Inc.
Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
February 09, 2022 08:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
January 31, 2022 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 03, 2022 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_Twitter-profile_full-logo.png
Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.
December 20, 2021 07:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...